DBV Technologies SA (DBVT)
0.67
0.00 (0.00%)
USD |
NASDAQ |
May 06, 16:00
0.6779
+0.01
(+1.18%)
After-Hours: 20:00
DBV Technologies Research and Development Expense (Quarterly): 12.78M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.78M |
| September 30, 2023 | 13.80M |
| June 30, 2023 | 17.62M |
| March 31, 2023 | 16.04M |
| December 31, 2022 | 29.61M |
| September 30, 2022 | 15.10M |
| June 30, 2022 | 18.61M |
| March 31, 2022 | 12.22M |
| December 31, 2021 | 11.67M |
| September 30, 2021 | 16.32M |
| Date | Value |
|---|---|
| June 30, 2021 | 20.18M |
| March 31, 2021 | 22.16M |
| December 31, 2020 | 26.39M |
| September 30, 2020 | 25.75M |
| June 30, 2020 | 21.93M |
| March 31, 2020 | 27.53M |
| December 31, 2019 | 34.50M |
| September 30, 2019 | 21.21M |
| December 31, 2018 | 33.26M |
| September 30, 2018 | 31.58M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
11.67M
Minimum
Dec 2021
34.50M
Maximum
Dec 2019
20.19M
Average
19.40M
Median
Research and Development Expense (Quarterly) Benchmarks
| Biophytis SA | -- |
| Edap TMS SA | 2.370M |
| Cellectis SA | 25.53M |
| Genfit SA | -- |
| Adaptimmune Therapeutics PLC | 33.21M |